La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Genetic Signatures Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Neil Gunn

Amministratore delegato

AU$189.8k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	1.8yrs
Durata media del Consiglio di amministrazione	6.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

AMMINISTRATORE DELEGATO

Neil Gunn (63 yo)

less than a year

Mandato

AU$189,763

Compensazione

Dr. Neil Gunn serves as Independent Board Director of Rarecells Diagnostics SAS since September 2022. He serves as Independent Director at NeoGenomics, Inc. since June 26, 2023. He serves as Director at Ne...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Neil Gunn	Interim CEO & Non-Executive Director	less than a year	AU$189.76k	Nessun dato
Michael Aicher	Executive Director of US Operations & Executive Director	10.6yrs	AU$178.42k	Nessun dato
Christopher Abbott	Founder & Chairman Emeritus	no data	Nessun dato	0% A$ 0
Karl Pechmann	CFO, COO & Company Secretary	1.2yrs	Nessun dato	Nessun dato
Douglas Millar	Chief Scientific Officer	23.6yrs	AU$308.55k	Nessun dato
Rebecca Abbatantuono	Global Head of People & Culture	less than a year	Nessun dato	Nessun dato
Neralie Coulston	Global Head of Regulatory Affairs	1.8yrs	Nessun dato	Nessun dato
Jackson Jones	Chief Commercial Officer	1.8yrs	Nessun dato	Nessun dato

1.8yrs

Durata media

Gestione esperta: Il team dirigenziale di GSS non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Neil Gunn	Interim CEO & Non-Executive Director	3.3yrs	AU$189.76k	Nessun dato
Michael Aicher	Executive Director of US Operations & Executive Director	10.6yrs	AU$178.42k	Nessun dato
Christopher Abbott	Founder & Chairman Emeritus	no data	Nessun dato	0% A$ 0
Anthony Radford	Non-Independent Non-Executive Director	8.9yrs	AU$72.42k	0.14% A$ 241.0k
Caroline Waldron	Non-Executive Director	2.3yrs	AU$72.42k	0.0099% A$ 16.8k
Nickolaos Samaras	Independent Non-Executive Chairman	16.6yrs	AU$129.84k	1.1% A$ 1.9m
Stéphane Chatonsky	Director	less than a year	Nessun dato	0.084% A$ 141.0k

6.1yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GSS sono considerati esperti (durata media dell'incarico 6.1 anni).

Genetic Signatures Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Genetic Signatures Limited Announces Changes to Board of Directors

Director recently bought AU$59k worth of stock

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Less than half of directors are independent

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Recent updates

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media